<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754958</url>
  </required_header>
  <id_info>
    <org_study_id>VRMRI_LNCO2021</org_study_id>
    <nct_id>NCT04754958</nct_id>
  </id_info>
  <brief_title>Virtual Reality to Alleviate Claustrophobia During MRI</brief_title>
  <acronym>CLAUSTROVR</acronym>
  <official_title>Evaluation of the Benefit of Virtual Reality to Alleviate Claustrophobia During MRI Clinical Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ecole Polytechnique Fédérale de Lausanne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ecole Polytechnique Fédérale de Lausanne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates if our Virtual Reality (VR) simulation inside the MRI efficiently&#xD;
      alleviates symptoms of claustrophobia for patients during the MRI examination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety of claustrophobic patients during MRI scan leads to movements of patients (which&#xD;
      cause imaging artefacts), interruptions or even abortions of imaging scans, eventually&#xD;
      requiring to reschedule the examination. Improving these symptoms by creating a VR&#xD;
      experiences adapted to the physical constraints of the MRI environment, such as &quot;disappearing&#xD;
      the scanner&quot;, not only improves the subjective experience of the participant, but has&#xD;
      immediate impacts the time spent on the examination, on personnel costs, and resource&#xD;
      availability (scanner time).&#xD;
&#xD;
      This study aims at comparing claustrophobic patients in an A|B group design with or without&#xD;
      VR intervention. Primary outcomes include subjective reports from patients (Acceptability and&#xD;
      Demand) and practitioners (Implementation, Practicality, Adaptation, Integration, Expansion).&#xD;
      Secondary outcomes include scanning efficacy based e.g. on the imaging quality, number of&#xD;
      times a scan is interrupted by the user and the total duration of a scan. Another&#xD;
      non-claustrophobic patients' group will be tested for for obtaining feedback on the general&#xD;
      benefit of VR immersion on patients' experience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 25, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Invervention group / no intervention group (standard of care)</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety level</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>Questionnaire on anxiety during scan (9 items)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interruption</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>Record of interruption due to claustrophobia during MRI scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI Image quality</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>Evaluation of MRI image quality for medical care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Claustrophobia</condition>
  <arm_group>
    <arm_group_label>VR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard care during MRI scan, patient receives VR intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No VR</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care during MRI scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immersion in virtual reality using Nordic Neurolab(™) Visual System</intervention_name>
    <description>In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.</description>
    <arm_group_label>VR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  indicating suffering from claustrophobia&#xD;
&#xD;
          -  Be aged between 18 and 40 year-old&#xD;
&#xD;
          -  Being able to give consent&#xD;
&#xD;
          -  Being able to understand and speak French or English&#xD;
&#xD;
          -  Being MRI-compatible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epilepsy or illnesses affecting the brain, such as HIV, Lyme disease or meningitis&#xD;
&#xD;
          -  Psychiatric disorders, such as schizophrenia, autism, obsessive compulsive disorder.&#xD;
&#xD;
          -  History of 1 year or more of addiction to drugs such as cannabis, alcohol, cocain,&#xD;
             heroine, LSD.&#xD;
&#xD;
          -  Taking sleeping pills or anti-anxiety medication before the exam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Blanke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ecole Polytechnique Fédéralede Lausanne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaf Blanke, Prof</last_name>
    <phone>0216939621</phone>
    <phone_ext>+41</phone_ext>
    <email>olaf.blanke@epfl.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Herbelin, Dr</last_name>
    <phone>21 693 04 67</phone>
    <phone_ext>+41</phone_ext>
    <email>bruno.herbelin@epfl.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve (HUG)</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Isabel Vargas, Prof</last_name>
      <email>Maria.I.Vargas@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Karl-Olof Lovblad, Prof</last_name>
      <email>Karl-Olof.Lovblad@hcuge.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ecole Polytechnique Fédérale de Lausanne</investigator_affiliation>
    <investigator_full_name>Olaf Blanke</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

